Navigation Links
Echo Therapeutics Hires Two Seasoned Medical Device and Diagnostics Executives
Date:3/22/2011

anufacture.  Most recently Mr. Garibotto was a co-founder of Insulet Corp. where he served as Vice President of R&D and Engineering.  At Insulet, he led the development and commercialization of the OmniPod Insulin Management System, a new class of product for the delivery of insulin, which has gained international acceptance.  Mr. Garibotto holds a B.S. in Industrial Technology from the University of Massachusetts and a Masters in Business Administration from Northeastern University.

Mr. Gary has more than 25 years of experience in the design and development of sensor-based diagnostics and data connectivity systems for the point-of-care and diabetes markets.  As R&D Venture Director for Abbott Diabetes Care, he led the design and development of hospital-based point-of-care and consumer diabetes testing systems.  As General Manager of Breathquant Medical, Mr. Gary led the design and successful clinical trials for Breathquant's novel low-cost diagnostic system for the rapid detection of pulmonary embolism.  Mr. Gary holds a B.S. in Bioengineering and an M.S. in Chemical Engineering from Columbia University and an MBA from Boston University.

About Echo TherapeuticsEcho Therapeutics is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units.  Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking StatementsThe statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks
'/>"/>

SOURCE Echo Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... YORK , Sept. 3, 2015 About dry ... dryness of eyes due to deficient tear production or ... syndrome is of two types: aqueous tear deficient dry ... dry eye, lacrimal glands do not produce enough tears, ... Meibomian glands secrete lipids to slow tear evaporation and ...
(Date:9/3/2015)... -- As part of its ongoing commitment to provide exceptional ... Katz , MD, MPH, cardiac surgeon and chief medical ... implanted the first HeartMate 3 left ventricular assist device ... part of the prestigious MOMENTUM 3™ Clinical Trial. Bon ... United States—and the first in central Virginia—chosen to evaluate ...
(Date:9/3/2015)... , Sep. 03, 2015 ... of the "Investigation Report on China,s Trastuzumab Market, ... by Genentech, trastuzumab was approved by FDA to be ... trade name of Herceptin, a major product of Roche. ... 6.56 billion around the world. After entering ...
Breaking Medicine Technology:Global Dry Eye Syndrome Market 2015-2019 2Bon Secours' Patient FIRST in Central Virginia to receive New Life-saving Care 2Bon Secours' Patient FIRST in Central Virginia to receive New Life-saving Care 3Bon Secours' Patient FIRST in Central Virginia to receive New Life-saving Care 4Investigation Report on China's Trastuzumab (Genentech) Market, 2010-2019 2
... Reportlinker.com announces that a new market research report ... Teva Pharma. Industries Ltd: PharmaVitae Profile ... This analysis examines the historical ... pharmaceutical sector. The profile encompasses global company strategy, ...
... Zimmer Holdings, Inc. (NYSE: ZMH ; SIX: ZMH), ... Zimmer NexGen LPS-Flex Mobile Bearing Knee with ... States.  The LPS-Flex Mobile Bearing knee provides a revolutionary anteriorly-positioned ... (ACL), replicating the anatomic center of knee rotation. ...
Cached Medicine Technology:Reportlinker Adds Teva Pharma. Industries Ltd: PharmaVitae Profile 2Zimmer Introduces a Move Forward in Mobile Bearing Knee Design 2Zimmer Introduces a Move Forward in Mobile Bearing Knee Design 3
(Date:9/3/2015)... , ... September 03, 2015 , ... ... and Indiana University, Indianapolis, have chosen Center for Hospice Care (CHC) for ... institutions will train at CHC as part of fulfilling their requirements for obtaining ...
(Date:9/3/2015)... Georgia (PRWEB) , ... September 03, 2015 , ... ... spread of disease in Haiti, has partnered with Slingshot® Product Development Group to ... electricity or running water. Michael Wahl with DriButts plans to bring 600 DriButts ...
(Date:9/3/2015)... ... September 03, 2015 , ... Results of a ... Healthcare Research and Policy Analysis has found physician leadership development training programs to ... percent of respondents said their organizations conduct some kind of physician leadership development ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... ... care community to be situated at 4400 Columbine Drive in Bellingham, Washington. Silverado ... 2016, and has been carefully designed to serve up to 80 people living ...
(Date:9/3/2015)... ... September 03, 2015 , ... IQ Formulations ... 2015 by economic development group GrowFL and the Edward Lowe Foundation. The leading ... for this prestigious award, which recognizes growing second-stage companies “that demonstrate high performance ...
Breaking Medicine News(10 mins):Health News:Physicians from Mayo Clinic and Indiana University to Complete Hospice & Palliative Medicine Training at Center for Hospice Care 2Health News:DriButts Diapers Rely on Slingshot Help in Haiti 2Health News:DriButts Diapers Rely on Slingshot Help in Haiti 3Health News:Survey finds growing movement for physician leadership training 2Health News:Survey finds growing movement for physician leadership training 3Health News:Site Dedication Ceremony to Celebrate New Silverado Memory Care Community 2Health News:IQ Formulations Hailed Among Florida Companies to Watch for 2015 2Health News:IQ Formulations Hailed Among Florida Companies to Watch for 2015 3
... , ... skin brightener, has now introduced anti aging ingredients to its already popular product to make ... ... SkinBright the most complete skin brightener available. , , ,Age spots, liver spots, brown patches, ...
... ... to grow, unethical companies are beginning to produce imitation products to benefit from the success ... phony products before they become too large to control. , ... Milford, CT (PRWEB) March 16, 2010 -- They say imitation ...
... ... Marketing Excellence Europe Conference explores how global medical device manufacturers are leveraging integrated, domain-specific ... ... 16, 2010 -- Model N , the leader in Revenue Management solutions for ...
... ... income in the current economy, and who are looking to better their health, too, can ... enlisting interested business leaders nationwide., , ... (PRWEB) March 16, 2010 -- Independent businessman Brad Aspin and leading health and wellness ...
... NANJING , March 16 /PRNewswire-Asia/ -- Simcere Pharmaceutical ... leading pharmaceutical company,specializing in the development, manufacturing, and marketing of ... for the quarter and the fiscal year ended December ... -- Total revenue was RMB539.4 million (US$79.0 million) ...
... Fla. , March 15 ARMSRx ... leader in transparent pharmacy benefits assessment, has received many requests ... the first quarter closes in 2010.  The September 26, ... First DataBank (FDB) and Medispan may very well leave employers ...
Cached Medicine News:Health News:Best Selling, Non Toxic Skin Brightener Does the Job Using Safe, Healthy Ingredients and Introduces New Anti Aging Ingredients 2Health News:IN Pet Supplements Face Challenges in New China Market as Imitation Products Continue to Baffle Consumers 2Health News:IN Pet Supplements Face Challenges in New China Market as Imitation Products Continue to Baffle Consumers 3Health News:Media Alert: Model N and International Medical Device Leader to Share Insights on Maximizing Sales Performance with Revenue Management 2Health News:Brad Aspin and Health and Wellness Company GBG Now Looking for Leaders Nationwide 2Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 2Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 3Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 4Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 5Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 6Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 7Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 8Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 9Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 10Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 11Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 12Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 13Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 14Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 15Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 16Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 17Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 18Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 19Health News:ARMSRx Evaluation of AWP Neutrality 2Health News:ARMSRx Evaluation of AWP Neutrality 3
... Our breadth of infectious disease ELISA products ... With standard assay protocols for faster integration ... ELISA products provide increased reliability and run-to-run ... antibody detection assays for a wide range ...
... offer a complete line of ... state-of-the-art monoclonal and monoclonal/polyclonal antibody-based ... of enteric pathogens in fecal ... for Clostridium difficile, Entamoeba histolytica, ...
Inquire...
... CHEK test is a rapid immunoassay to detect ... specimens. The test uses antibodies specific for toxins ... >90% sensitivity and >99% specificity compared to tissue ... and toxin B, the risk of false negative ...
Medicine Products: